Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HHH NASDAQ:KYMR NASDAQ:LNTH NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHHHHoward Hughes$66.91+0.4%$64.30$61.01▼$91.07$3.97B1.14418,401 shs344,453 shsKYMRKymera Therapeutics$86.21+3.9%$82.85$36.65▼$103.00$6.82B2.02547,902 shs625,216 shsLNTHLantheus$104.52+0.2%$90.68$47.25▼$104.57$6.79B-0.031.01 million shs687,403 shsTSHATaysha Gene Therapies$5.71+2.3%$5.77$2.25▼$7.30$1.60B1.192.18 million shs2.05 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHHHHoward Hughes+0.57%+2.87%+4.27%+4.79%-4.69%KYMRKymera Therapeutics+3.92%+16.30%+0.72%+9.09%+78.16%LNTHLantheus+0.19%+3.51%+8.36%+31.49%+29.44%TSHATaysha Gene Therapies+2.33%+3.82%-14.39%+27.17%+113.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHHHHoward Hughes$66.91+0.4%$64.30$61.01▼$91.07$3.97B1.14418,401 shs344,453 shsKYMRKymera Therapeutics$86.21+3.9%$82.85$36.65▼$103.00$6.82B2.02547,902 shs625,216 shsLNTHLantheus$104.52+0.2%$90.68$47.25▼$104.57$6.79B-0.031.01 million shs687,403 shsTSHATaysha Gene Therapies$5.71+2.3%$5.77$2.25▼$7.30$1.60B1.192.18 million shs2.05 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHHHHoward Hughes+0.57%+2.87%+4.27%+4.79%-4.69%KYMRKymera Therapeutics+3.92%+16.30%+0.72%+9.09%+78.16%LNTHLantheus+0.19%+3.51%+8.36%+31.49%+29.44%TSHATaysha Gene Therapies+2.33%+3.82%-14.39%+27.17%+113.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHHHHoward Hughes 1.33Sell$85.0027.03% UpsideKYMRKymera Therapeutics 2.96Moderate Buy$117.1435.87% UpsideLNTHLantheus 2.73Moderate Buy$101.86-2.55% DownsideTSHATaysha Gene Therapies 3.00Buy$11.64103.79% UpsideCurrent Analyst Ratings BreakdownLatest TSHA, HHH, KYMR, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026KYMRKymera Therapeutics Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$97.006/8/2026KYMRKymera Therapeutics Brookline Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.005/8/2026LNTHLantheus CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/8/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$85.00 ➝ $115.005/8/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$95.00 ➝ $100.005/7/2026LNTHLantheus The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$94.005/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.005/1/2026LNTHLantheus B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHHHHoward Hughes$1.47B2.70$6.22 per share10.75$49.69 per share1.35KYMRKymera Therapeutics$39.21M180.86N/AN/A$19.42 per share4.44LNTHLantheus$1.54B4.41$6.40 per share16.34$16.43 per share6.36TSHATaysha Gene Therapies$9.77M167.95N/AN/A$0.90 per share6.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHHHHoward Hughes$131.88M$2.0432.8019.62N/A8.04%5.41%1.61%N/AKYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)LNTHLantheus$233.56M$4.1525.1919.36N/A18.05%29.32%15.00%8/5/2026 (Estimated)TSHATaysha Gene Therapies-$109M-$0.38N/AN/AN/AN/A-56.07%-40.16%8/11/2026 (Estimated)Latest TSHA, HHH, KYMR, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026HHHHoward Hughes$0.08$0.14+$0.06$0.14N/A$235.92 million5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/6/2026Q1 2026TSHATaysha Gene Therapies-$0.10-$0.12-$0.02-$0.12$0.76 millionN/A4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million3/19/2026Q4 2025TSHATaysha Gene Therapies-$0.11-$0.08+$0.03-$0.08$1.89 million$5.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHHHHoward HughesN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHHHHoward Hughes1.971.581.58KYMRKymera TherapeuticsN/A10.8110.81LNTHLantheus0.472.832.64TSHATaysha Gene Therapies0.2314.0414.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHHHHoward Hughes93.83%KYMRKymera TherapeuticsN/ALNTHLantheus99.06%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipHHHHoward Hughes48.00%KYMRKymera Therapeutics15.98%LNTHLantheus1.70%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHHHHoward Hughes60859.62 million31.01 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableTSHATaysha Gene Therapies180287.36 million276.50 millionOptionableTSHA, HHH, KYMR, and LNTH HeadlinesRecent News About These CompaniesIs Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?June 11 at 4:57 PM | finance.yahoo.comTaysha Gene Therapies Grants Restricted Stock Units and Stock Options to New EmployeesJune 5, 2026 | quiverquant.comQTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Buy" by BrokeragesJune 4, 2026 | americanbankingnews.comTaysha Gene Therapies Shareholders Back Governance and LeadershipJune 2, 2026 | tipranks.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY), Corcept Therapeutics (CORT) and Taysha Gene Therapies (TSHA)June 2, 2026 | theglobeandmail.comTaysha Gene Therapies: Shortened Timeline Increases The PotentialJune 1, 2026 | seekingalpha.comASPIRE Rett Syndrome Trial Puts Taysha’s TSHA-102 Gene Therapy in Focus for InvestorsMay 22, 2026 | tipranks.comNeedham ups Taysha target on ‘derisking’ TSHA-102 newsMay 15, 2026 | msn.comTaysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026May 14, 2026 | finance.yahoo.comCanaccord Keeps Buy Rating on Taysha (TSHA) After Q1 HighlightsMay 11, 2026 | insidermonkey.comTaysha Gene Therapies Ramps Up Ahead of TSHA-102 BLAMay 10, 2026 | tipranks.comAssessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent VolatilityMay 9, 2026 | finance.yahoo.comTaysha Gene Therapies, Inc. Q1 2026 Earnings Call SummaryMay 9, 2026 | finance.yahoo.comTaysha outlines PPQ completion by Q4 2026 while targeting a TSHA-102 BLA option based on a 6-month interim analysisMay 7, 2026 | seekingalpha.comTaysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comTaysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6April 29, 2026 | globenewswire.comHas Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?April 28, 2026 | finance.yahoo.comTaysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual MeetingApril 27, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTSHA, HHH, KYMR, and LNTH Company DescriptionsHoward Hughes NYSE:HHH$66.91 +0.25 (+0.38%) Closing price 06/12/2026 03:59 PM EasternExtended Trading$66.91 0.00 (-0.01%) As of 06/12/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.Kymera Therapeutics NASDAQ:KYMR$86.21 +3.25 (+3.92%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$86.22 +0.02 (+0.02%) As of 06/12/2026 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Lantheus NASDAQ:LNTH$104.52 +0.20 (+0.19%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$104.52 0.00 (0.00%) As of 06/12/2026 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Taysha Gene Therapies NASDAQ:TSHA$5.71 +0.13 (+2.33%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$5.54 -0.18 (-3.06%) As of 06/12/2026 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
